Medibanx provides longitudinal clinical data obtained with patient consent to accelerate drug development timelines. By offering access to comprehensive patient data, the company addresses the inefficiencies in clinical trials and regulatory processes.
Funding
$255K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The drug development process is often slowed by difficulties in accessing comprehensive, longitudinal clinical data, which is essential for understanding disease progression and treatment efficacy. Inefficient clinical trials and regulatory processes further exacerbate these delays.
Solution
Medibanx facilitates faster drug development by providing access to longitudinal clinical data obtained with patient consent. The company aggregates and curates patient data from various sources, ensuring data privacy and compliance with regulations. This comprehensive dataset enables researchers and pharmaceutical companies to gain deeper insights into disease mechanisms, identify potential drug targets, and optimize clinical trial design. By streamlining access to high-quality patient data, Medibanx accelerates the development of new therapies and improves patient outcomes.
Target Audience
Medibanx primarily serves pharmaceutical companies, biotechnology firms, and academic research institutions involved in drug discovery and clinical development.
Features
- Secure data aggregation from diverse clinical sources, including electronic health records, wearables, and patient-reported outcomes.
- Longitudinal data curation and standardization to ensure data quality and interoperability.
- Advanced analytics tools for identifying disease biomarkers and predicting treatment response.
- Patient consent management platform to ensure data privacy and compliance with regulations.
- Secure data access and sharing platform for researchers and pharmaceutical companies.